

“Combination therapy for reduction of toxicity of chemotherapeutic agents”

5 The present invention relates to a unique combination therapy for minimising dosage required of chemotherapeutic agents for their use in antiviral, antibacterial, antiparasitic and anticancer chemotherapy. This invention also relates to the use of the compounds of the present invention including precursor molecules, derivatives, metabolites, analogues, mimic molecules and to compositions containing the compounds of the present invention including precursor molecules, derivatives, metabolites, analogues, mimic molecules for use in a combination
10 therapy with chemotherapeutic agents for their use in antiviral, antibacterial, antiparasitic and anticancer chemotherapy.

Cancer develops from changes in the DNA, or genetic material, of the body's cells, causing them to develop into precancerous lesions. Such lesions exhibit a strong
15 tendency to develop into malignant tumours, or cancer. Such lesions include lesions of the breast (that can develop into breast cancer), lesions of the skin (that can develop into malignant melanoma or basal cell carcinoma), colonic adenomatous polyps (that can develop into colon cancer), and other such neoplasms.

20 Cancer may take years to develop. The process typically begins with some disruption to the DNA of a cell, the genetic code that directs the life of the cell. Many things, such as diet, tobacco, sun exposure or certain chemicals can cause such disruptions. Some cells will enter a precancerous phase, known as dysplasia. Some cells will also enter the state of *carcinoma in situ*, in which the cancer cells
25 are restricted to a microscopic site and do not pose a great threat. Eventually, unless the body's own immune system takes care of the wayward cells either on its own or by being enhanced by specific chemicals, a tumour will develop. It may take as long as 30 years for a tumour to go through the entire process and become large enough to produce clinical symptoms.

30 Anyone can get cancer, including children, but it is most common in people over the age of 50. This year about 1.22 million people in the United States will be

diagnosed with cancer (not including the more than 1 million annual cases of basal and squamous-cell skin cancers.) About 563,000 people will die of cancer this year.

Treatment for cancer has progressed rapidly over the last 30 years. Doctors generally prescribe three main treatments for cancer: surgery, radiation therapy, chemotherapy or a combination of these. Choosing a course of medical treatment depends largely on the cancer type, stage of progression, and location.

Chemotherapy uses poison drugs that take advantage of cancer cells' rapid growth and consumption of large amounts of nutrients. Chemotherapy side effects include nausea, bone marrow suppression and temporary full or partial hair loss. One class of chemotherapeutic agents, the nucleotide analogues, are used as anticancer agents because they interfere with the synthesis of DNA and thereby preferentially kill rapidly dividing cells such as tumour cells. Some of the nucleotide analogues commonly used in chemotherapy are 6-mercaptopurine, 5-flourouracil, 5-iodo-2'-deoxyuridine and 6-thioguanidine. Each of these compounds disrupts the normal replication process by interfering with the formation of correct Watson-Crick base-pairing.

Physicians inject these drugs into the bloodstream, where they travel throughout the body, consumed by every cell. Rapidly growing cancerous cells consume much more of the poisonous drugs than do normal cells. As a result, the drugs destroy cancerous cells faster than normal cells. However, chemotherapy drugs act on all the patient's cells -- the cancerous cells and the healthy cells. A physician's challenge is to administer the drugs to kill only the cancer cells, not the healthy cells. Unfortunately, most chemotherapeutic drugs have serious side effects that prohibit their long-term use, or use in otherwise healthy individuals with precancerous lesions. These side effects, which are a result of non-specific toxicity of the drugs, immunosuppression and other toxicities. For this reason there is a need to identify new drug candidates for therapy of patients with precancerous lesions that can be combined with existing chemotherapeutic drugs, whereby the dose can be reduced, diminishing the toxicity and serious side effects in humans.

Acquired Immunodeficiency Syndrome (AIDS) is one of the most significant infections to appear in the last decade. This epidemic is not confined to a single segment of the population nor is its spread blocked by natural barriers or

international boundaries. Millions have died in Africa and many more individuals are infected worldwide. In the United States more than 100,000 people have died and at least 1 million more are presently infected with the virus. This pandemic shows no signs of abating.

5

AIDS was first diagnosed in male homosexuals who exhibited a variety of infections of fungal (*Candida albicans*), protozoal (*Pneumocystis carinii*), and viral (Herpes zoster) origin. Many of these individuals also had an increased incidence of kaposi sarcoma and lymphoma. They had a depressed T helper/T suppressor lymphocyte cell ratio and an absence of delayed hypersensitivity responses. Collectively, these observations suggested a deficiency in cell-mediated immunity.

10

It is strongly suspected that the causative agent in AIDS is an RNA retrovirus called the human immunodeficiency virus (HIV-1 or HIV-2). HIV possesses an envelope glycoprotein (gp120) that has a high affinity for the CD₄ receptor on T helper cells and other target cells. These other target cells include bone marrow stem cells, macrophages, endothelial cells, glial cells, lymph node, dendritic cells, bowel enterochromaffin cells, cervical epithelium and possibly Langerhans cells. However, it is the effects of HIV on T-helper cells that are the best known. The infectious process begins when the virus penetrates the body and enters the blood stream. Binding of HIV to CD₄ target cells involves interaction of the external envelope glycoprotein molecule gp120 with the CD₄ molecule, although other cell receptors may be involved. The virus next enters the target cell, or is internalized, through fusion of the viral envelope with the target cell membrane. Through this fusion, the virus loses its coat, and releases its RNA core and reverse transcriptase enzyme into the host cell cytoplasm.

15

20

25

The HIV reverse transcriptase enzyme copies the RNA message producing first a single-stranded, and then a double-stranded, DNA (circular complementary DNA). This newly formed double-stranded DNA becomes incorporated into the host chromosomal DNA once it enters the host cell nucleus. This incorporated viral DNA may remain dormant or, upon activation, will produce viral messenger RNA (mRNA). The viral mRNA codes for proteins that are important in viral replication.

30

Glycoprotein will then envelop the RNA genome resulting in the production of infectious viral particles; completed viral particles are then released to infect other cells.

5 Current approaches to HIV treatment generally involve immunotherapy (e.g., vaccines against whole killed HIV and a variety of HIV surface glycoproteins) directed at the HIV as well as pharmacological intervention in the HIV infectious process. In theory, any of the steps of viral replication or release could be points of pharmacological attack against the virus. The major chemotherapeutic attack by
10 available drugs has been at the level of inhibition of viral reverse transcriptase using nucleotide and nucleotide analogues. The first drug licensed for use in HIV treatment became available in 1987; it was azidothymidine (AZT). In the early 1990's, dideoxyinosine (DDI) and dideoxycytidine (DDC) were approved by the FDA. AZT and DDI were approved for monotherapy while DDC is used in
15 combination with one of the other drugs. However, when administered to patients, nucleotide and nucleoside analogues have shown toxicity to liver, bone marrow, and the nervous system. Side effects include bone marrow suppression (anemia granulocytopenia), headache, malaise, nausea, pancreatitis, peripheral neuropathy, minor GI and CNS symptoms, and oral ulcers. In the case of antiviral therapy,
20 nucleoside analogs have been rarely curative, and the side effects that arise during chronic administration of the drug often cause therapy to be discontinued or altered. In the case of cancer therapy, where intent is to kill the cancer cells, the compound and protocol (dose, method of administration, timing of doses) must be carefully designed and monitored to minimize the damage to non-cancerous
25 tissues.

Many different treatment regimens are and have been used to treat the HIV infection and AIDS, which occurs after the latent infection. While they might prolong survival and possibly minimize symptoms, in view of the mounting worldwide
30 concern regarding the epidemic, these treatments have not been generally successful and cause considerable side effects. Therefore, the continuing hard reality is that once the virus enters the body and begins the uncoating process, a fatal outcome is almost inevitable. Such an outcome reveals the continuing need

for additional research to discover a method of treatment, which can suppress the reproduction of latent viruses such as HIV without inducing toxicity. For this reason there is a need to identify new drug candidates for therapy of patients with HIV infection and AIDS that can be combined with existing chemotherapeutic drugs, whereby the dose can be reduced, diminishing the toxicity and serious side effects in humans.

Parasitic infections are a major worldwide health problem. The global prevalence of human parasitic infections already exceeds 50% and is increasing. Diverse factors are responsible including population crowding; poor sanitation and health education; inadequate control of parasite infections and reservoirs of infection; increased world travel; population migration and resistance to the agents used for chemotherapy or control of vectors.

Despite encouraging progress in identifying promising molecular targets for intervention with vaccines, chemotherapy remains the single most effective method to control most parasitic infections. However, to be used for mass chemotherapy, an ideal antiparasitic agent should be safe at high therapeutic doses with minimal toxicity. Few antiparasitic drugs meet these criteria. For this reason there is a need to identify new drug candidates for therapy of patients with parasitic infections that can be combined with existing chemotherapeutic drugs, whereby the dose can be reduced, diminishing the toxicity and serious side effects in humans. Furthermore, several antibiotics are not in current use due to their toxicity profile. It would be advantageous similarly to identify new drug candidates for therapy of patients with bacterial infections that can be combined with existing chemotherapeutic drugs, whereby the dose can be reduced, diminishing the toxicity.

Additionally, the suppression of immune response to limit rejection in tissue transplantation by the use of nucleotide and nucleoside analogues is limited by the toxicity of the compounds. The identification of new drug candidates for therapy of patients with tissue transplants that can be combined with existing chemotherapeutic drugs, whereby the dose can be reduced, is necessary.

5 The correlation between the combination therapy including the compounds of the present invention, circiliol, precursor molecules, derivatives, metabolites, analogues and/or mimic molecules, antiviral and anticancer chemotherapy was not recognised prior to the work of the applicant. Accordingly the following provides information on each of these topics.

10 The present invention provides methods and pharmaceutical compositions for repressing reproduction of latent viruses, such as HIV, parasites, bacteria and for anticancer therapy in humans and animals, by the generally concurrent administration of at least one chemotherapeutic agent with compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof.

15 The present invention relates to a composition comprising at least one of the compounds of the present invention.

20 The present invention also relates to a pharmaceutical formula comprising a composition comprising at least one of the compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof, at least one chemotherapeutic agent and a pharmaceutically acceptable carrier. The advantage of such a pharmaceutical formula is that the antimetabolites, nucleotide and/or nucleoside analogues can be administered in much lower doses than normally administered, thereby greatly
25 reducing their toxicity while increasing their therapeutic index. The synergistic effect of the chemotherapeutic agents in combination with the compounds of the present invention provides an enhanced efficacy despite the low dose of chemotherapeutic agent administered.

30 The present invention is also directed to the use of a pharmaceutical formulation for the manufacture of a medicament for treatment of a mammal suffering from a neoplasia and/or viral, bacterial and/or parasite infection and/or suppression of immune response rejection in tissue transplantation.

The present invention is also directed to a method for manufacturing a medicament for treating neoplasia and/or viral, bacterial and/or parasite infection and/or suppression of immune response rejection in tissue transplantation utilizing a specific treatment protocol.

The present invention is directed to a method of inhibiting neoplastic cells by exposing those cells to a pharmacologically effective amount of pharmaceutical formulations comprising compositions containing those compounds of the present invention with pharmaceutical acceptable additives, diluents, carriers and excipients and at least one chemotherapeutic agent. Such compounds are effective at eliminating and inhibiting the growth of neoplasias such as precancerous lesions, tumours and cancer growth. One of the advantages of utilising such compositions is that they are low in toxicity, which in combination with their mechanism of action diminishes resistance development.

The present invention provides the compounds of the present invention, circiliol, including their precursor molecules, derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers and excipients and at least one chemotherapeutic agent and methods comprising inhibiting tumour growth or treating cancer by administering one or more of the compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers and excipients in combination with at least one chemotherapeutic agent.

The present invention also provides products that are useful for treating neoplasia and/or viral, bacterial and/or parasite infection and/or suppression of immune response rejection in tissue transplantation with minimal toxic side effects unlike the high toxicity associated with standard chemotherapeutic agents.

The present invention is also directed to a pharmaceutical composition comprising a biologically active amount of at least one compound of the present invention.

The present invention is also directed to providing pharmaceutical formulations for treating various neoplasias and/or viral, bacterial and/or parasite infections and/or suppression of immune response rejection in tissue transplantation.

5 The present invention is also directed to providing a method for treating various neoplasias and/or viral, bacterial and/or parasite infections and/or suppression of immune response rejection in tissue transplantation.

10 Treatment according to the present invention can be effected when the subject is a neonate. Administration is carried out prior to delivery of the neonate and/or during delivery of the neonate. Prophylactic treatment of HIV⁺ pregnant mothers prevent the viral transmission to the fetus by being able to administer lower less toxic levels of chemotherapeutic agents in combination with the compounds of the present invention.

15 These and other objects of the present invention will become apparent from the description of the invention disclosed below, which descriptions are intended to limit either the spirit or scope of the invention but are only offered as illustrations of the preferred embodiments of the invention.

20 The present invention is directed to the treatment, inhibition and/or prevention of viral, bacterial and/or parasite infections and/or suppression of immune response rejection in tissue transplantation and/or tumours and/or cancer growth and more particularly to treating neoplasia and/or HIV.

25 The invention features a method of treating neoplasia and/or viral, bacterial and/or parasite infection and/or suppression of immune response rejection in tissue transplantation, which includes administering to an animal an effective amount of a pharmaceutical formulation comprising a composition comprising at least one of the compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof, at least one chemotherapeutic agent and a pharmaceutically acceptable carrier.

30 The invention is directed to a method of treating tumours and/or viral, bacterial and/or parasite infections and/or suppression of immune response rejection in tissue transplantation comprising administering a biologically active amount of a pharmaceutical formula comprising a composition comprising at least one of the

compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof, at least one chemotherapeutic agent and a pharmaceutically acceptable carrier.

5 The invention features a method of treating cancer and/or viral, bacterial and/or parasite infections and/or suppression of immune response rejection in tissue transplantation comprising administering to a patient in need thereof a cancer and/or viral, bacterial and/or parasite treatment and/or suppression of immune response rejection in tissue transplantation an effective amount of a pharmaceutical formula comprising a composition comprising at least one of the
10 compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof, at least one chemotherapeutic agent and a pharmaceutically acceptable carrier.

The inventions objects include the provision of pharmaceutical formulations and compounds, which are suitable for making the formulations. Other objects are to
15 provide methods to use the formulations.

It was surprisingly found that when the compounds of the present invention were administered in combination with chemotherapeutic agents, the proliferation of neoplastic cells was inhibited, which is manifested, pursuant to one aspect of the present invention, in a broad-spectrum anti-neoplastic activity with minimal toxicity.

20 The compounds of the present invention are individually diverse, but collectively all act to inhibit the propagation of neoplastic cells, cancers, cancer growth and/or tumours.

The invention also features a method of treating neoplasia and/or viral, bacterial and/or parasite infection and/or suppression of immune response rejection in tissue
25 transplantation comprising administering to a patient an effective amount of a pharmaceutical composition including at least one compound of the present invention, at least one chemotherapeutic agent and a pharmaceutically acceptable carrier.

Treating neoplasia in a patient includes achieving, partially or substantially, one or
30 more of the following: arresting the growth or spread of a cancer, reducing the extent of a cancer (e.g., reducing size of a tumour or reducing the number of

affected sites), inhibiting the growth rate of a cancer, and ameliorating or improving a clinical symptom or indicator associated with a cancer (such as tissue or serum components).

5 In accordance with the present invention, a method is provided to treat or prevent viral, bacterial and/or parasite infection and/or suppression of immune response rejection in tissue transplantation comprising administering to a subject an effective amount of one or more of the compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof in combination with a chemotherapeutic agent.

10 The present invention also provides the use of one or more of the compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof in combination with a chemotherapeutic agent, for the manufacture of a medicament for a viral, bacterial and/or parasite infection and/or suppression of immune response rejection in tissue transplantation.

15 The present invention also provides compounds for use in a method of treatment of a viral, bacterial and/or parasite infection and/or suppression of immune response rejection in tissue transplantation, said method comprising administering one or more to a subject.

DETAILED DESCRIPTION OF THE INVENTION

25 The compounds of the present invention comprise circiliol and corresponding pharmaceutically acceptable precursor molecules, derivatives, metabolites, analogues, mimic molecules and mixtures thereof.

The present invention relates to a composition comprising one or more of the compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof.

30 In another embodiment of the invention, the composition includes but is not limited to one or more of the following components: Circiliol; 6,7-dimethoxy-5,3'4'-

trihydroxyflavone; 6-hydroxy-2,3,4-trimethoxy acetophenone; 2-(3,4-dibenzoyloxybenzoyloxy)-4,5,6-trimethoxy acetophenone; 3'4'-dibenzoyloxy-2-hydroxy-4,5,6-trimethoxydibenzoyl methane; 6,7-dibenzoyloxy-5,6,7-trimethoxy flavone; 3,4-dihydroxy-5,6,7-trimethoxy flavone; 3,4-diacetoxy-5,6,7-trimethoxy flavone, their
5 derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

In one embodiment, the chemotherapeutic agents are antimetabolites, nucleotide
10 and/or nucleoside analogues. Novel antimetabolites, nucleotide and/or nucleoside analogues are disclosed in US 6,127,540; US 5,837,871; US 5,879,700; US 5,977,061; US 5,981, 507; US 5,994,321; and US 6,071,922 and are incorporated by reference.

In another embodiment the nucleotide analogues are pyrimidine antagonists,
15 preferably selected from but not limited to the group comprising: 5-flourouracil; cytosine arabinoside; Azacitidine. In another embodiment the nucleotide analogues are purine antagonists, preferably selected from but not limited to the group comprising: 6-mercaptopurine; azathioprine; 5-iodo-2'-deoxyuridine; 6-thioguanine; 2-deoxycoformycin, cladribine, cytarabine, fludarabine, mercaptopurine, thioguanine, pentostatin.

20 In another embodiment the nucleoside analogues are preferably selected from but not limited to the group comprising: purine and pyrimidine nucleosides; ara-nucleosides; amino-nucleosides; aza-nucleosides; In another embodiment the nucleoside analogues are preferably selected from but not limited to the group comprising: AZT (zidovudine); ACV; valacyclovir; famciclovir; acyclovir; cidofovir;
25 penciclovir; ganciclovir; Ribavirin; ddC; ddl (zalcitabine); lamuvidine; Abacavir; Adefovir; Didanosine; gemcitabine; d4T (stavudine); 3TC; BW 1592; PMEA/bis-POM PMEA; ddT, HPMPG, HPMPA, PMEA, PMEG, dOTC; DAPD; Ara-AC, pentostatin; dihydro-5-azacytidine; tiazofurin; sangivamycin; Ara-A (vidarabine); 6-MMPR; 5-FUDR (floxuridine); cytarabine (Ara-C; cytosine
30 arabinoside); 5-azacytidine (azacitidine); HBG [9-(4-hydroxybutyl)guanine], (1S,4R)-4-[2-amino-6-cyclopropyl-amino)-9H-purin-9-yl]-2-cyclopentene-1-me

thanol succinate ("159U89"), uridine; thymidine; idoxuridine; 3-deazauridine; cyclocytidine; dihydro-5-azacytidine; tricitabine, ribavirin and fludrabine.

In another embodiment, the chemotherapeutic agents selected from the group but are not limited to: Chloroquin, primaquine, mefloquine, pyrimethamine-sulfadoxone, 5 atoraquone/dapsone; halofantrine; artemisinin derivatives; atoraquone + proguanil, co-artemether; podophyllotoxin; pentamidine, diloxanide furoate, metronidazole, tindazole, tetracycline, quinacrine, stibogluconate, amphotericin B, quinine, doxycycline, trimethoprim-sulfamethoxazole, metronidazole, nifurtimox, suramin, melarsoprol, benznidazole, their metabolites, salts derivatives or any other anti-parasitic agent 10 thereof.

In another embodiment, the chemotherapeutic agents selected from the group but are not limited to: mitomycin C, nalidixic acid, puromycin, sanamycin, and actinomycin.

In another embodiment, the chemotherapeutic agents selected from the group but are not limited to: N⁶-(Δ^2 -isopentyl) adenosine, N⁶-(Δ^2 -isopentyl) adenosine-5'- 15 monophosphate, N⁶-(Δ^2 -isopentyl) adenosine-3',5'-cyclic monophosphate, benzyladenosine, N⁶- benzyladenosine-5'-monophosphate, N⁶- benzyladenosine-3',5'-cyclic monophosphate, furfuryladenosine, N⁶- furfuryladenosine -5'- monophosphate, N⁶- furfuryladenosine -3',5'-cyclic monophosphate, N-(purin- 20 6ylcarbamoyl)-o-chloroaniline ribonucleoside, N-(purin-6ylcarbamoyl)-o-chloroaniline ribonucleoside-5'-monophosphate, N⁶-adamantyladenosine, N⁶-adamantyladenosine-5'-monophosphate, N-(purin-6ylcarbamoyl)-o-octylamine ribonucleoside, N-(purin-6ylcarbamoyl)-o-octylamine ribonucleoside-5'-monophosphate, N-(purin-6ylcarbamoyl)-o-octylamine ribonucleoside-3',5'-cyclic monophosphate, N⁶-(Δ^2 - 25 isopentyl)-2-methylthioadenosine, N⁶-(4-hydroxy-3-methyl-trans-2-butenyl)adenosine, N⁶-(3-chloro-trans-2-butenyl) adenosine, surfinal adenosine and preferred metabolites including N⁶-(Δ^2 -isopentyl) adenine, 6-N-(3-methyl-3-hydroxybutylamino) purine, adenine, hypoxanthine, uric acid and methylated xanthines.

30 In a further or alternative aspect of the invention, there is provided a method for the treatment of a viral, bacterial and/or parasite infection and/or suppression of immune response rejection in tissue transplantation comprising the step of administering an effective dose of a compound of the present invention as defined hereinabove or a

pharmaceutically acceptable derivative thereof combined with at least one
chemotherapeutic agent. By combining the compounds of the present invention with
chemotherapeutic agents a synergistic effect is observed and a much lower dosage
of the chemotherapeutic agents is required, achieving the desired therapeutic effect
5 while limiting the toxicity to the patient.

As will be appreciated by those skilled in the art, references herein to treatment
extends to prophylaxis as well as to the treatment of established infections of
symptoms.

10

By the term "pharmaceutically acceptable derivative" is meant any pharmaceutically
acceptable salt, ester, or salt of such ester of a compound of the present invention, or
any other compound which, upon administration to the recipient, is capable of
providing (directly or indirectly) a compound of the present invention or an active
15 metabolite or residue thereof.

Pharmaceutically acceptable salts of the compounds of the present invention include
those derived from pharmaceutically acceptable inorganic and organic acids and
bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric,
20 perchloric, fumaric, maleic, phosphoric, lactic, salicylic, succinic, p-toluenesulphonic,
tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-
sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not in
themselves pharmaceutically acceptable, may be useful in the preparation of salts
useful as intermediates in obtaining the compounds of the invention and their
25 pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth
metal (e.g. magnesium), ammonium and $N(R')_{3.4+}$ (where R' is C_{1-4}
alkyl) salts.

30 In a preferred embodiment, the nucleoside analogue is a phosphate ester selected
from the group comprising: Acyclovir; 1-beta-D-arabinofuranosyl-E-5-(2-
bromovinyl)uracil; 2'-fluorocarbocyclic-2'-deoxyguanosine; 6'-fluorocarbocyclic-2'-
deoxyguanosine; 1-(beta-D-arabinofuranosyl)-5(E)-(2-iodovinyl)uracil; {(1r-1.alpha.,

2.beta., 3.alpha.)-2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-6H-purin-6-one}
Lobucavir; 9H-purin-2-amine, 9-((2-(1-methylethoxy)-1-((1-
methylethoxy)methyl)ethoxy)methyl)-(9Cl); trifluorothymidine; 9- \rightarrow (1,3-dihydroxy-2-
propoxy)methylguanine (ganciclovir); 5-ethyl-2'-deoxyuridine; E-5-(2-bromovinyl)-
5 2'-deoxyuridine; 5-(2-chloroethyl)-2'-deoxyuridine; buciclovir; 6-deoxyacyclovir; 9-(4-
hydroxy-3-hydroxymethylbut-1-yl)guanine; E-5-(2-iodovinyl)-2'-deoxyuridine; 5-
vinyl-1-beta-D-arabinofuranosyluracil; 1-beta-D-arabinofuranosylthymine; 2'-nor-
2'deoxyguanosine; 1-beta-D-arabinofuranosyladenine.

In another embodiment, the nucleoside phosphate ester is in the form of a
10 pharmaceutically acceptable salt. In another embodiment, the salt is selected from
the group consisting of sodium, potassium, ammonium, and hydrogen salts.

In certain embodiments the compounds of the present invention and
chemotherapeutic agents are combined with a physiological carrier for the treatment
15 of the pathophysiological state.

In another embodiment the pharmaceutical formulation is delivered to infected cells
by incorporating the pharmaceutical formulation into liposomes or carbohydrate
vehicles.

In another embodiment the pharmaceutical formulation further includes a
pharmaceutically acceptable carrier, which in one embodiment is a cyclodextrin,
alpha-cyclodextrin, beta-cyclodextrin, (beta-hydroxypropylcyclodextrin) gamma-
cyclodextrin and in another embodiment is vitamin E oil, DMSO and/or ethanol.

25 The compounds of the present invention can be formulated and administered as
free bases or in the form of their pharmaceutically acceptable salts for purposes of
stability, convenience of crystallisation, increased solubility, and the like.

As used herein, the term "neoplasia" or neoplasm covers dysplasia, precancerous
lesions, cancerous lesions, neoplastic cells, cancer, cancer growth, tumours,
30 benign tumours, malignant tumours, solid tumours, carcinomas, etc.

As used herein, the term "precancerous lesion" includes syndromes represented by
abnormal neoplastic, including dysplastic, changes of tissue. Examples include

precancerous growths in colonic, breast, renal, central nervous, gastric, or lung tissues, or conditions such as dysplastic nevus syndrome, a precursor to malignant melanoma of the skin. Examples also include, in addition to dysplastic nevus syndromes, polyposis syndromes, colonic polyps, precancerous lesions of the cervix (i.e., cervical dysplasia), prostatic dysplasia, bronchial dysplasia, breast, bladder and/or skin and related conditions (e.g., actinic keratosis), whether the lesions are clinically identifiable or not.

The pharmaceutical formulations of the present invention can be administered to a mammal having a susceptible cancer, i.e. a malignant cell population or tumour.

10 The combination of the compounds of the present invention and chemotherapeutic agents are effective on human tumours in vivo as well as on tumour cell lines in vitro. The pharmaceutical formulations of the present invention may be particularly useful for the treatment of solid tumours for which relatively few treatments are available. Such tumours include epidermoid and myeloid tumours, acute or

15 chronic, nonsmall cell, squamous. Specific cancers which may be mentioned as susceptible to treatment by administration of pharmaceutical formulations in accordance with the present invention include prostate cancer, colon cancer, small cell lung cancer, large cell lung cancer, lung adenocarcinoma, epidermoid lung cancer, melanoma (including amelanotic subtypes), renal cell carcinoma, gastric carcinoma, cancers of the central nervous system (based on the likelihood that the compounds will cross the blood cell barrier) including brain tumours, neuroblastomas, gastric carcinoma, breast cancer, ovarian cancer, testicular cancer, lymphoma and leukaemia, oesophageal cancer, stomach cancer, liver cancers, prostate cancer, cervical cancer, adrenal cancer, oral or mucosal cancer,

20 bladder cancer, pancreatic cancer, lymphoma, Hodgkins disease, sarcomas. Haematopoietic cell cancers such as B cell leukaemia/lymphomas, myelomas, T-cell leukemias/lymphomas, small cell leukemias/lymphomas, null cell, sezary, monocytic, myelomonocytic and Hairy cell leukemias. These lymphomas/leukemias can be either acute or chronic. Other cancers may also be

25 susceptible to treatment with the compounds of the present invention. The activity can readily be measured using standardised tests known to those skilled in the art.

As used herein, the term "carcinomas" refers to lesions that are cancerous. Examples include malignant melanomas, breast cancer, and colon cancer. As used herein, the term "neoplasm" refers to both precancerous and cancerous lesions.

5 As used herein, the terms "inhibit" or "inhibiting," mean decreasing tumour cell growth rate from the rate that would occur without treatment and/or causing tumour mass to decrease. Inhibiting also includes causing a complete regression of the tumour. Thus the compounds of the present invention can be either cytostatic or cytotoxic to the tumour cells.

10 In another embodiment, the subjects viral infection is selected from a DNA virus infection or an RNA virus. In a preferred embodiment, the DNA virus infection or the RNA virus infection is selected from a HIV, SHIV, SIV, FIV, HSV, CMV, HAV, HBV, HCV, HDV, HEV, EBV, BVDV, HSV-1, HSV-2, HSV-6, HHV-6, HHV-8, retrovirus infection, a togavirus infection, a flavivirus infection, a rubivirus infection,
15 a pestivirus infection, a lipid envelope virus infection, a filovirus, a picornavirus infection, a rhinovirus infection, a coronavirus infection, a respiratory syncytial virus infection, a poliovirus infection, a parainfluenza virus infection, influenza virus infection, hantavirus, adeno-associated virus, measles virus, poxvirus, filovirus, human papilloma virus and animal papilloma virus infection.

20 In another embodiment, the patient is suffering from one or more complications or co-infections associated with AIDS, AIDS related syndromes, including cachexia and/or wasting syndrome.

25 In another embodiment, the parasite infection is a *Trypanosoma*, *Plasmodium*, *Cryptosporidium*, *Entamoeba*, *Balantidium*, *Leishmania*, *Pneumocystis*, *Trichomoniasis* or *Toxoplasma* parasite infection.

The present invention also relates to the administration of a pharmaceutical
30 formulation to a patient infected with a retrovirus or is suffering with AIDS and co-infected with *Trypanosoma*, *Plasmodium*, *Cryptosporidium*, *Entamoeba*, *Balantidium*, *Leishmania*, *Pneumocystis*, *Trichomoniasis* or *Toxoplasma* parasites

or a *Mycoplasma* bacterium.

Another aspect of the present invention is the effective treatment of malaria, sleeping sickness, African trypanosomiasis, Chagas disease, American trypanosomiasis, cryptosporidiosis, amebiasis, balantidiasis, giardiasis, leishmaniasis, pneumocystosis, trichomoniasis, and toxoplasmosis with the pharmaceutical formulation of the present invention.

Accordingly, the present invention contemplates administering daily to a subject an amount of pharmaceutical formulation of the present invention that is clinically effective in treating or preventing a parasite infection, which the subject suffers or is at risk from infection. Illustrative parasites against which the invention can be applied are *Trypanosoma*, *Plasmodium*, *Cryptosporidium*, *Entamoeba*, *Balantidium*, *Leishmania*, *Pneumocystis*, *Trichomoniasis* or *Toxoplasma* parasites wherein the *Trypanosoma* parasites are selected from the group, but is not limited to *Trypanosoma cruzi*, *Trypanosoma brucei*, *Trypanosoma gambiense*, *Trypanosoma rhodesiense*, wherein the *Plasmodium* parasites are selected from the group, but is not limited to *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium ovale*, *Plasmodium berghei*, wherein the *Entamoeba* is *Entamoeba histolytica*, wherein the *Balantidium* is *Balantidium coli*, wherein the *Leishmania* is selected for the group, but is not limited to *Leishmania braziliensis*, *Leishmania mexicana*, *Leishmania donovani*, *Leishmania tropica*, wherein the *Pneumocystis* is *Pneumocystis carinii*, wherein the *Trichomoniasis* is *Trichomoniasis vaginalis*, and the *Toxoplasma* parasite is *Toxoplasma gondii*, among other parasites.

In another embodiment, the bacterial infection is an intracellular bacterial infection, an extracellular bacterial infection, a mycoplasma infection, a *Listeria* infection or a *Mycobacterium* infection; a *Streptococcus* infection, a *Staphylococcus* infection, a *Vibrio* infection, a *Salmonella* infection; a *Shigella* infection, an enterotoxigenic, enteropathogenic, enteroinvasive or enterohemorrhagic *E. coli* infection, a *Yersinia* infection, a *Campylobacter* infection, a *Pseudomonas* infection, a *Borrelia* infection, a *Legionella* infection and a *Haemophilus* infection; pulmonary *Aspergillosis*, mucosal or oropharyngeal candidiasis and juvenile paracoccidiomycosis; or any

combination of the above.

In another embodiment, the composition further includes a pharmaceutically acceptable carrier.

5

In another embodiment, a pharmaceutical formulation or method in the prophylaxis and therapy of viral infections or a complication or consequence thereof is provided.

10 In particular the invention relates to the use a pharmaceutical formulation of the present invention, in the prophylaxis and therapy of viral infections, viral replication and the development and prevention of the deficiency of the immune system resulting in the development of opportunistic infections and certain cancers. More especially the invention relates to the use of a pharmaceutical formulation of the present invention, in the prophylaxis and therapy of viral infections, an example of which is the retrovirus, thought to be responsible for the Acquired Immune Deficiency Syndrome (AIDS) and AIDS related syndromes, believed to result from infection from 15 the Human Immunodeficiency Virus (HIV), antibodies to which are found in almost all individuals diagnosed with AIDS.

20 Other embodiments provide a pharmaceutical formulation or method to treat a viral infection or to ameliorate one or more symptoms associated with a viral infection such as a flaviviral or retroviral infection comprising administering to an infected patient an effective amount of a pharmaceutical formulation as disclosed herein. It is an object of the present invention to provide a pharmaceutical formulation of the present invention for treatment, therapeutic or prophylaxis, against a viral, 25 bacterial and/or parasitic infection. The compounds of the present invention are synergistic agents that enhance the efficacy of the chemotherapeutic agents, enabling their administration at much lower doses to achieve the therapeutic benefit, while minimizing the toxicity.

30 Accordingly disclosed herein is a pharmaceutical formulation or a method for treating a viral, parasite and/or bacterial infection and/or suppression of immune response rejection in tissue transplantation; for use in treating any infection, preventing a future infection and/or minimizing the effects of a future infection by a

virus, bacteria and/or parasite comprising administering to a patient in need thereof a prophylactically or therapeutically effective amount of a composition comprising at least one of the compounds of the present invention, with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof, at least one
5 chemotherapeutic agent and a pharmaceutically acceptable carrier.

The advantage of this is that an effective anti-viral is provided that has minimal risk of conferring resistance and incurring toxicity.

10 In one embodiment of the invention the infection is a viral infection, in another embodiment the viral infection is caused by a retrovirus, in another embodiment, the retroviral infection is caused by HIV or AIDS virus, Herpes virus, cytomegalovirus, or an animal virus, and in an additional embodiment the viral infection is caused by a lipid envelope virus.

15 In another embodiment, the pharmaceutical formulation is used to treat AIDS related syndromes, including cachexia and/or wasting syndrome.

One useful property of the pharmaceutical formulation of the present invention is
20 their anti-viral activity, which is manifested, pursuant to one aspect of the present invention, in a broad-spectrum anti-viral activity. Accordingly, the present invention contemplates administering daily to a subject an amount of a pharmaceutical formulation of the present invention that is clinically effective in treating or preventing a viral infection, which the subject suffers or is at risk from infection.

25 Illustrative viruses against which the invention can be applied are HIV, cytomegalovirus (CMV), a KS-producing herpes virus, Kaposi's Sarcoma-associated herpes virus, the virus of the genus hepatitis, a virus of the genus picornaviruses, a virus of the genus molluscipoxvirus, hantaviruses, among other viruses.

30 Additionally, the present invention is also broadly directed providing the use of the pharmaceutical formulation of the present invention in the treatment (i.e., in the sense of treating an existing infection, preventing a future infection, minimizing the

effect of a future infection and/or enhancing the performance of a vaccine) of all infections which are not retroviral infection, several representative examples of which include one or more kind of Mycoplasma, and/or one or more diseases caused by Mycoplasmas and/or one or more of the following infections: hairy
5 leukoplakia, oral candidosis, mouth ulcerations – aphthous/herpetic/bacterial, fungal candida, squamous oral carcinoma, Kaposi's sarcoma oral lesions, periodontitis, necrotizing gingivitis, human papilloma virus, rhinovirus and arboviral molluscum contagiosum, orafacial herpes zoster, Epstein barr virus, rotaviruses, togaviruses, including alpha viruses (also known as arboviruses, group A),
10 flaviviruses (also known as arboviruses, group B, such as yellow fever, as well as hepatitis C and hepatitis G), rubiviruses (also known as rubella viruses e.g., human rubella virus), pestiviruses (also known as mucosal disease viruses, such as bovine virus diarrhoea virus BVDV, hog cholera virus, and sheep border disease), as well as any other non-retroviral viral induced infections. Thus virus infections that may
15 be treated include but are not limited to HIV, SIV, FIV, FELV, SHIV, Kaposi's Sarcom-associated herpes virus and other herpes viruses (e.g. HSV-1, HSV-2, human herpes virus 6 (HHV-6) and HHV-8), the viruses associated with hepatitis (HAV, HBV, hepatitis C virus [HCV]), and human cytomegalovirus, togaviruses and flaviviruses, e.g., California encephalitis virus, St. Louis encephalitis virus, western
20 equine encephalitis virus, eastern equine encephalitis virus, Colorado tick fever virus, LaCrosse encephalitis virus, Japanese encephalitis virus, yellow fever virus, Venezuelan equine encephalitis virus, Murray valley fever virus, tick-borne encephalitis virus, GB virus A, GB virus B, GB virus C, Dengue virus 1, Dengue virus 2, Dengue virus 3, Dengue virus 4, Semliki Forest virus, Sinbis virus,
25 picornaviruses, rhinoviruses, coronaviruses, respiratory syncytial viruses, polioviruses, parainfluenza viruses and influenza viruses (including type A, type B, and type C.

Pursuant to a preferred embodiment of the invention, an effective amount of a
30 pharmaceutical formulation of the present invention thus administered is such as to produce a circulating concentration of the compounds of the present invention, including precursor molecules, derivatives, metabolites, analogues, mimic molecules,

and at least one chemotherapeutic agent sufficient to reduce viral loads as monitored by, e.g., viral titre methods or by PCR.

According to a further aspect of the invention the pharmaceutical formulations is formulated in a liposome.

5

In another embodiment of the invention, liposomes are provided carrying the pharmaceutical formulations of the present invention targeted to HIV infected cells by putting antibodies to the HIV coat protein gp160 or gp120 on its surface. The advantage of this is that the liposome can selectively target HIV infected cells.

10 As used herein, the terms subject and patient are used interchangeably. Subjects and patients are mammals.

The pharmaceutical formulations of the present invention are useful antineoplastic agents i.e. to inhibit tumour cell growth in vitro and in vivo, in mammalian hosts, such as humans or domestic animals, and are particularly effective against solid
15 tumours and multidrug resistant tumours. Thus the invention provides a method comprising inhibiting cancer cells, by contacting said cells, in vitro and in vivo with an effective amount of a pharmaceutical formulation of the present invention. The invention also provides a therapeutic method comprising treating cancer (i.e. inhibiting tumour cell growth) by administering a pharmaceutical formulation of the
20 present invention to a mammal in need of such therapy.

The present invention is also directed to pro-drug compounds analogous to the active compounds disclosed herein. Such compounds are generally themselves inactive or low in activity, but are converted into active compounds. Thus, for example, pro-drugs such as the methyl ester of any acid functionality, which is not
25 active *per se* or has very low activity could be hydrolysed, either uncatalytically or catalytically with an enzyme such as an esterase, to an active compound. Such pro-drug compounds could well be the preferred therapeutic form of the present compounds. These analogous prodrugs can be produced from active compounds based on procedures and factors that are well known to one of ordinary skill in the
30 art. Accordingly as used in the present application, "pro-drug analogue" means "a chemical which is relatively non-toxic and pharmacologically inert but which can be transformed *in vivo* to a pharmacologically active drug". More specifically it means

a precursor molecule, derivative, metabolite or analogue of the compounds of the present invention which have low or no ability as antineoplastic, antiviral, antibacterial, antiparasitic agents until converted in the body to a derivative, metabolite or analogue with such ability or abilities. Such pro-drugs should have
5 favourable properties such as enhanced absorption, water solubility, lower toxicity, or better targeting to the tumour cell (such as by reason of greater affinity to the tumour cell or a larger quantity of activating enzyme in the tumour cell as opposed to a normal cell so that larger concentrations of the active compound are produced in the tumour cell). Examples of such compounds are esters, such as methyl,
10 ethyl, phenyl, N,N-dimethylaminoethyl, acyl derivatives such as benzoyl, p-N,N-dimethylaminobenzoyl, N,N-dimethylaminoglycyl, peptide derivatives such as γ -glutamyl, glycyl, D-Val-Leu-Lys.

The pharmaceutical formulation according to the present invention can be administered to a patient in any of a wide range of routes. Thus, with regard to the
15 types of formulations in which the active compounds according to the present invention can be administered, as well as any additives can be included with the active compounds in the formulations, and the possible routes of administration, it is well known to those of skill in the art that such formulations can be provided in a wide variety of types, and it is within the skill of the ordinary artisans to select a
20 specific formulation and route of administration and then test suitability for use. By way of example but not limitation, suitable routes include enteric, parenteral, topical, oral, rectal, nasal or vaginal routes. Parenteral routes include subcutaneous, intramuscular, intravenous, intraperitoneal, intradermal and sublingual administration. Also, compositions may be implanted into a patient or
25 injected using a drug delivery system.

The pharmaceutical formulation according to the present invention may be administered locally or systemically. By systemic administration means any mode or route of administration that results in effective amounts of active ingredient appearing
30 in the blood or at a site remote from the route of administration of the active ingredient.

Further, the pharmaceutical formulation according to the present invention may be

administered intermittently. The advantage of this is that it allows the patient to suspend therapy for periods without the worry of inactivity of the drug resulting from the development of resistant cells.

- 5 The pharmaceutical formulation according to the invention may be formulated for enteral, parenteral or topical administration. Indeed all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.

10 Compounds useful in the methods of this invention may be formulated into compositions together with pharmaceutically acceptable carriers for oral administration in solid or liquid form, or for rectal administration, although carriers for oral administration are most preferred.

15 Pharmaceutically acceptable carriers for rectal administration are preferably suppositories that may contain, in addition to the compounds of the present invention, excipients such as cocoa butter or a suppository wax.

20 Pharmaceutically acceptable carriers for oral administration include capsules, tablets, pills, powders, troches and granules. In such solid dosage forms, the carrier can comprise at least one inert diluent such as sucrose, lactose or starch. Such carriers can also comprise, as is normal practice, additional substances other than diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, troches and pills, the carriers may also comprise buffering agents. Carriers such as tablets, pills and granules can be prepared with enteric coatings on the surfaces of the tablets, pills or granules. Alternatively, the enterically coated compound can be pressed into a tablet, pill, or granule, and the
25 tablet, pill or granules for administration to the patient. Preferred enteric coatings include those that dissolve or disintegrate at colonic pH such as shellac or Eudraget S. Additional pharmaceutically acceptable carriers include liquid dosage forms for oral administration, e.g. pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used
30 in the art, such as water. Besides such inert diluents, compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, and sweetening, flavouring and perfuming agents.

In one embodiment, the pharmaceutical formulation has an enteric coating. In another embodiment, the enteric coating is made of a polymer or copolymer. In a preferred embodiment, the polymer or copolymer is selected from the group consisting of poly(lactic-glycolic acid) polyester, cellulose acetate phthalate, hydroxypropyl-methyl cellulose phthalate poly(butyl methacrylate), (2-dimethyl aminoethyl) methacrylate, and methyl methacrylate.

In accordance with the present invention, the expression "micronized" means that the compound has been micronized in accordance with any process for micronizing, a number of which are known in the art. The micronized particles preferably include a percentage of particles, which are of a diameter, which is about 10 microns, or less, preferably, 5 microns or less. For example, in a preferred aspect of the invention, at least 80% of the particles in a formulation of micronized particles have a diameter of less than 5 microns. An alternative to micronizing a compound is to solubilize the compound and put it into liposomes of appropriate size. The manufacture of liposomes and the insertion of active ingredients into such liposomes are well known in the art.

Suitable injectable solutions include intravenous, subcutaneous and intramuscular injectable solutions. Examples of injectable forms include solutions, suspensions and emulsions. Typically the compound(s) is injected in association with a pharmaceutical carrier such as normal saline, Ringers solution, dextrose solution and other aqueous carriers known in the art. Appropriate non-aqueous carriers may also be used and examples include cyclodextrin, preferably hydroxypropyl beta cyclodextrin, mixed oils (vitamin E oil), polyethylene glycol and ethyl oleate. A preferred carrier is cyclodextrin in water. Frequently, it is desirable to include additives in the carrier such as buffers and preservatives or other substances to enhance isotonicity and chemical stability.

The pharmaceutical formulation can also be administered topically. Suitable formulations for topical administration include creams, gels, jellies, muclriages, pastes and ointments. The compounds may be formulated for transdermal administration, for example in the form of transdermal patches so as to achieve systemic administration.

The pharmaceutical formulation may also be administered in the form of an implant.

The pharmaceutical formulation may also be administered in the form of an infusion solution or as a nasal inhalation, aerosol or spray.

5 In another embodiment, the composition is incorporated in a pharmaceutically acceptable carrier, diluents, vehicles and the like for systemic administration by feeding. An example of such a carrier is cyclodextrin (α -cyclodextrin, β -hydroxypropylcyclodextrin or γ -cyclodextrin), DMSO, ethanol.

10 The pharmaceutically acceptable carrier, chemotherapeutic agents and compounds of this invention are formulated into unit dosage forms for administration to a patient. The dosage levels of active ingredient (i.e. compounds of this invention) in the unit dosage may be varied so as to obtain an amount of active ingredient effective to achieve lesion-eliminating activity in accordance with the desired method of administration (i.e., oral or rectal). The selected dosage level therefore depends upon the nature of the active compound administered, the route of
15 administration, the desired duration of treatment, individual needs and other factors. If desired, the unit dosage may be such that the daily requirement for active compound is in one dose, or divided among multiple doses for administration, e.g., two to four times per day.

20 With regard to dosage and duration of treatment according to any aspect of the present invention, it is recognized that the ability of an artisan skilled in pharmaceutical administration of drugs to determine suitable dosages depending on many inter-related factors is well known, and skilled artisans are readily able to monitor patients to determine whether treatment should be started, continued, discontinued or resumed at any given time. For example, dosages of the
25 compounds are suitably determined depending on the individual cases taking symptoms, age and sex of the subject and the like into consideration. The amount of the compound to be incorporated into the pharmaceutical composition of the invention varies with dosage route, solubility of the compound, administration route, administration scheme and the like. An effective amount for a particular patient
30 may vary depending on factors such as the condition being treated, the overall health of the patient and the method, route and dose of administration. The clinician using parameters known in the art makes determination of the appropriate

dose. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved. Suitable dosages can be determined by further taking into account relevant disclosure in the known art. In one embodiment, the unit dose
5 comprises 5-500 mg of active ingredient consisting of at least one compound of the present invention.

The pharmaceutical formulation of this invention is preferably packaged in a container (e.g. a box or bottle, or both) with suitable printed material (e.g. a package insert) containing indications, directions for use, etc.
10 The pharmaceutical formulations containing the active compounds or pro-drugs of the present invention can be formulated so as to be specifically targeted to tumours and viral, bacterial and/or parasite containing cells. The compounds can be attached to the reagent that is capable of binding a tumour and/or viral, bacterial and/or parasite-associated antigen. For example, the compounds of the present
15 invention could be covalently attached to a monoclonal antibody such as directed to a tumour-associated antigen. The antigen may be located on a tumour/virus/ bacterial/parasite or in the tumour/virus cell area. Such linkages can be made through peptide bond formation with amino groups of an antibody. Suitable reagents include polyclonal and monoclonal antibodies. Accordingly, the present
20 invention also provides a method comprising treating cancer and/or viral/ bacterial/parasite infections by administering a pharmaceutical formulation of the present invention and a reagent (i.e. monoclonal or polyclonal antibody), which is capable of binding to a tumour/virus/ bacterial/parasite associated antigen.

In one embodiment, the liposomes or carbohydrate vehicles are targeted to HIV
25 infected cells by putting viral antibodies on its surface. In another embodiment, the viral antibodies are directed to the HIV coat protein gp160 and/or gp120.

The invention provides a method of treating a neoplasia and/or viral/ bacterial/parasite infection and/or suppression of immune response rejection in tissue transplantation comprising administering to a mammal in need thereof an
30 effective amount of a composition containing as an active ingredient therein at least one of the compounds of the present invention, with pharmaceutical acceptable

additives, diluents, carriers, excipients and pharmaceutical salts thereof, a chemotherapeutic agent and a pharmaceutically acceptable carrier.

The invention provides a method for manufacturing a medicament for treating neoplasia and/or viral/ bacterial/parasite infection and/or suppression of immune response rejection in tissue transplantation wherein the treatment protocol comprises:

Administering a first composition comprising at least one of the compounds of the present invention circiliol, precursor molecules, derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof and a pharmaceutically acceptable carrier;

later followed by a second composition comprising at least one conventional chemotherapeutic agent and a pharmaceutically acceptable carrier;

during the treatment protocol.

The present invention also provides a method of endowing a chemotherapeutic agent with substantially enhanced therapeutic efficacy and reduced toxicity, comprising:

- (a) providing a chemotherapeutic agent; and
- (b) combining the agent with one or more compounds of the present invention with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof and a pharmaceutically acceptable carrier thereof so as to reduce the cytotoxicity of the combination in comparison to the chemotherapeutic agent alone.

The invention further provides a pharmaceutical formulation for treating a cancer selected from the group consisting of small cell lung cancer, testicular cancer,

lymphoma, leukaemia, oesophageal cancer, stomach cancer, colon cancer, breast cancer, central nervous system cancer, liver cancer and prostate cancer, which comprising administering to a mammal in need thereof an effective amount of a composition containing as an active ingredient therein at least one of the
5 compounds of the present invention, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof.

The invention provides compositions comprising, the compounds of the present invention and at least one chemotherapeutic agent, to be used as anti-viral/
10 bacterial/parasite and/or anti-cancer agents.

The invention provides compositions comprising, the compounds of the present invention and at least one chemotherapeutic agent, to be used in the preparation of medicaments having anti-viral/ bacterial/parasite and/or anti-cancer activity.
15

The invention further provides, the use of the compounds of the present invention and at least one chemotherapeutic agent, is provided as anti-viral/ bacterial/parasite and/or anti-cancer agents.

20 In another embodiment, the use of the compounds of the present invention and at least one chemotherapeutic agent, is provided for the preparation of medicaments having anti-viral/ bacterial/parasite and/or anti-cancer activity.

In another embodiment, the compounds of the present invention and at least one chemotherapeutic agent, are provided, for the preparation of medicaments having activity against viral/ bacterial/parasite infections and/or cancer.
25

The invention also relates to a method of suppressing tumour growth in a mammal by administering to the mammal an amount of the compounds of the present invention, and a second chemotherapeutic agent effective to suppress tumour growth in the mammal. The second chemotherapeutic agent is an antimetabolite, nucleotide and/or nucleoside analogue. These compositions provide enhanced antitumour effect and may also prevent the development of metastases. In
30

particular, these compounds are useful for overcoming tumours that are drug resistant. These agents may be administered separately or as a cocktail. Administering the compound of the present invention or a derivative, metabolite, analogue or mimic molecule, thereof several hours prior to administering the chemotherapeutic agent may reduce toxicity. The compositions can be administered by any route.

The components of any of the pharmaceutical formulations disclosed herein can be administered simultaneously (in a combination formulation), essentially simultaneously (e.g., administration of each compound a few minutes or a few hours apart), or can be administered sequentially, e.g., several days apart, or more than a week apart. For example, a compound of the present invention, (and a conventional chemotherapeutic agent) can be administered together, or essentially simultaneously, e.g., administration of each compound a few minutes or a few hours apart, or can be administered sequentially, e.g., several days apart, or more than a week apart. All such variations in administration of the combination therapy are encompassed within the scope of the invention.

Further, the invention provides use of the composition in veterinary medicine, prophylactically and therapeutically in animal populations that are subject to infection that compromises immune response and cause infection.

In another embodiment, the subject or patient is an animal. The term animal as used herein includes, but is not limited to, mice, rats, domesticated animals such as but is not limited to, cats, dogs, and other animals but is not limited to, cattle, sheep, pigs, horses, camels, buffalo and primates such as but not limited to, monkeys, humans and more generally mammals.

Treatment according to the present invention can be effected when the subject or mammal is a neonate. Administration is carried out prior to delivery of the neonate and/or during delivery of the neonate.

Without further elaboration, it is believed that one skilled in the art can, using the

preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to test the various compounds of this invention and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way
5 whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures.

These and other features and advantages of the present invention will be more clearly understood with reference to the following description of some embodiments
10 thereof and with reference to the accompanying drawings in which: -

Fig. 1 A and B are graphs showing the IC₅₀ and IC₇₀ values of gemcitabine alone and in combination with circiliol respectively; and

15 Fig. 2 is graphs showing the dose dependent influence of circiliol on gemcitabine antitumour activity in both cell lines.

EXAMPLE 1

Gemcitabine (2', 2'-difluoro-2'-deoxycytidine, dFdC) is approved for the treatment
20 of locally advanced or metastatic pancreatic cancer, with additional activity in non small lung cancer alone and in combination with other cytotoxic agents like 5-flourouracil or cisplatin.

For this study, the *in vitro* growth of gemcitabine and circiliol, alone and in
25 combination was studied in the large cell lung cancer line LXFL 529L and the lung adenocarcinoma cell line LXFA 526L in a monolayer proliferation inhibition study.

TEST PROCEDURE

Cell lines

30 The cells were grown in monolayers and routinely passaged weekly. Stocks were not maintained more than 20 passages *in vitro*. Table 1 summarises the cell line characteristics.

TABLE 1: Characterisation of cell lines

Tumour type	Cell line	Histology in nude mice	Doubling time (hours)	Tumour formation in vivo
Lung (NSC)	LXFA 526L	adenocarcinoma	34	yes
	LXFA 529L	large cell	25	yes

NSC = non small cell

Assay

5 A modified propidium iodide assay (Dengler et al, 1995) was used to assess the effects of the 2 compounds and the combinations thereof. Cells were harvested from exponential phase cultures growing in RPMI 1640 medium supplemented with 10% foetal calf serum (FCS) and 1% gentamycin (100 U/ml) by trypsination, counted and plated in 96 well flat-bottomed microtitre plates (140 μ l cell
10 suspension, 5-20,000 cells/well). After a 24 hour recovery, to allow the cells resume exponential growth, 10 μ l of culture medium (6 control wells per plate) or culture medium containing gemcitabine and/or circiliol were added to the wells. Each drug concentration was plated in triplicate. Following 4 days of continuous drug exposure, the culture medium with or without drug was removed and 200 μ l of
15 an aqueous propidium iodide solution (6 μ g/ml) was added which then intercalates into the DNA of the dead cells. Fluorescence was measured using a Cytofluor 2350 microplate reader (excitation 530 nm, emission 620 nm). Growth inhibition was expressed as treated/control X 100 (%T/C); IC₅₀ and IC₇₀ values were determined by plotting drug concentration versus cell viability.

20

Drug application.

Circiliol, a crystalline compound, was dissolved in DMSO at a stock concentration of 100 mg/ml and stored at 4°C. Gemcitabine was used as its clinical formulation (Gemzar, Lilly) and dissolved for each experiment freshly in sterile water at a stock
25 concentration of 3.3 mg/ml.

Results and discussion

Both cell lines grew very well, with initial cell number increasing 4 fold.

Fluorescence units of controls ranged from 1.421 to 4.277. Clear dose response effects were seen. The determination of antiproliferation effects were repeated up to five times. The *in vitro* activity of circiliol is summarized in table 2.

5 **TABLE 2: *In vitro* activity (Test/Control %) of Circiliol**

Concentration of Circiliol ($\mu\text{g/ml}$)	3	30	300
LXFA 526L	93	53	56
LXFA 529L	102	49	39

MEDIAN OF 5 EXPERIMENTS

10 Circiliol alone was only moderately active *in vitro*. Concentration of 30 $\mu\text{g/ml}$ and 300 $\mu\text{g/ml}$ resulted in tumour growth inhibition in the range of 39% to 56% versus control in both cell lines. At concentrations of ≤ 3 $\mu\text{g/ml}$ circiliol no antitumour activity was evident *in vitro*.

15 Gemcitabine was potently active in both cell lines *in vitro*. The mean IC_{50} value was 0.63 $\mu\text{g/ml}$ in LXFA 526L adenocarcinoma cell lines and 0.36 $\mu\text{g/ml}$ in the LXFL 529L large cell lung cancer cell lines. The mean IC_{70} value was 5.7 $\mu\text{g/ml}$ in LXFA 526L and 0.64 $\mu\text{g/ml}$ in LXFL 529L.

20 Based on these results, gemcitabine was combined with 3 $\mu\text{g/ml}$ circiliol, which showed no tumour effects, and 30 $\mu\text{g/ml}$ circiliol which resulted in 50% inhibition of tumour growth *in vitro*. The results are presented in tables 3 and 4 and figures 1 and 2.

TABLE 3: IC_{50} values $\mu\text{g/ml}$ of gemcitabine alone and in combination with Circiliol

Concentration of Circiliol	0 $\mu\text{g/ml}$	+ 3 $\mu\text{g/ml}$	+ 30 $\mu\text{g/ml}$
LXFA 526L	0.63	0.072	n.d.
LXFA 529L	0.355	0.039	n.d.

25 **IC_{50} VALUES EVALUATED AS A MEDIAN OF 2-5 EXPERIMENTS PER CELL**

LINE.

n.d. NOT DETECTABLE

TABLE 4: IC₇₀ values $\mu\text{g/ml}$ of gemcitabine alone and in combination with Circiliol

Concentration of Circiliol	0 $\mu\text{g/ml}$	+ 3 $\mu\text{g/ml}$	+ 30 $\mu\text{g/ml}$
LXFA 526L	5.6	0.87	0.58
LXFA 529L	0.64	0.076	0.033

IC₇₀ VALUES EVALUATED AS A MEDIAN OF 2-5 EXPERIMENTS PER CELL

LINE.

Treatment of cells with 3 $\mu\text{g/ml}$ circiliol in combination with gemcitabine shifted IC₅₀ values from 0.63 $\mu\text{g/ml}$ to 0.072 $\mu\text{g/ml}$ in LXFA 526L cell lines and from 0.36 $\mu\text{g/ml}$ to 0.04 $\mu\text{g/ml}$ in the LXFA 529L cell lines. IC₇₀ values from 5.6 $\mu\text{g/ml}$ to 0.87 $\mu\text{g/ml}$ in LXFA 526L cell lines and from 0.64 $\mu\text{g/ml}$ to 0.076 $\mu\text{g/ml}$ in the LXFA 529L cell lines. Treatment of cells with 30 $\mu\text{g/ml}$ circiliol in combination with gemcitabine shifted IC₇₀ values from 5.6 $\mu\text{g/ml}$ to 0.58 $\mu\text{g/ml}$ in LXFA 526L cell lines and from 0.64 $\mu\text{g/ml}$ to 0.0033 $\mu\text{g/ml}$ in the LXFA 529L cell lines, corresponding to a 10 and 19 fold increase of antitumour activity respectively.

Circiliol alone demonstrates low activity in no small lung tumour cells LXFA 526L and LXFL 529L. However, when administered in combination with the antimetabolite gemcitabine a 6 to 8 fold increase in antitumour activity of gemcitabine is observed in vitro at a concentration of 3 $\mu\text{g/ml}$, which is inactive alone.

Pharmaceutically acceptable refers to those properties and/or substances, which are acceptable to the patient from a pharmacological/toxicological point of view including bioavailability and patient acceptance or to the manufacturing chemist from a physical-chemical point of view regarding composition, formulation, stability and isolatability.

The terms "comprise, comprised and comprising" and the terms "include, included and including" are used interchangeably in this specification and are to be afforded the widest interpretation.

- 5 The invention is not limited to the embodiments described above, but may be varied in both construction and detail within the scope of the claims.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
222